Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements

On April 6, 2026, Artelo Biosciences, Inc. received formal notification from The Nasdaq Stock Market LLC confirming that the company has regained compliance with two key listing requirements: Nasdaq Listing Rule 5550(b)(1) regarding minimum stockholders’ equity of $2.5 million, and Nasdaq Listing Rule 5620(a) regarding the requirement to hold an annual meeting of shareholders. This follows a previous exception granted by the Nasdaq Hearings Panel in February 2026. Despite regaining compliance, Artelo will be subject to a Mandatory Panel Monitor through April 6, 2027, pursuant to Nasdaq Listing Rule 5815(d)(4)(B). During this one-year monitoring period, if the company falls out of compliance with the equity rule again, it will not be eligible for a standard compliance plan or additional cure periods. Instead, Nasdaq staff will issue an immediate Delist Determination Letter, though the company would retain the right to request a new hearing. The company issued a press release regarding the successful compliance restoration on April 7, 2026.